Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sumit Basu

Showing results (31-40 of 39) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 39 results.
International Journal of Antimicrobial Agents|January 14, 2023
A single- and multiple-dose study to characterize the pharmacokinetics, safety, and tolerability of ceftolozane/tazobactam in healthy Chinese participantsNa Liu, Xiaohong Wang, Jixiang Zhu, et al.
Critical Care (London, England)|October 3, 2021
Ceftolozane/tazobactam probability of target attainment and outcomes in participants with augmented renal clearance from the randomized phase 3 ASPECT-NP trialAndrew F Shorr, Christopher J Bruno, Zufei Zhang, et al.
Drug Metabolism Reviews|March 8, 2017
Glucuronidation: driving factors and their impact on glucuronide dispositionGuangyi Yang, Shufan Ge, Rashim Singh, et al.
The AAPS Journal|June 15, 2023
Streamlining Food Effect Assessment - Are Repeated Food Effect Studies Needed? An IQ AnalysisFilippos Kesisoglou, Sumit Basu, Tejashree Belubbi, et al.
IEEE Journal of Biomedical and Health Informatics|February 24, 2022
A Comparison of Wearable Tonometry, Photoplethysmography, and Electrocardiography for Cuffless Measurement of Blood Pressure in an Ambulatory SettingRebecca Mieloszyk, Hope Twede, Jonathan Lester, et al.
The AAPS Journal|November 27, 2020
Correction to: Use of Physiologically Based Pharmacokinetic (PBPK) Modeling for Predicting Drug-Food Interactions: an Industry PerspectiveArian Emami Riedmaier, Kevin DeMent, James Huckle, et al.
The AAPS Journal|September 27, 2020
Use of Physiologically Based Pharmacokinetic (PBPK) Modeling for Predicting Drug-Food Interactions: an Industry PerspectiveArian Emami Riedmaier, Kevin DeMent, James Huckle, et al.
European Journal of Cancer (Oxford, England : 1990)|December 1, 2023
First-in-human study of naporafenib (LXH254) with or without spartalizumab in adult patients with advanced solid tumors harboring MAPK signaling pathway alterationsFilip Janku, Tae Min Kim, Gopakumar Iyer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 22, 2023
Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in <i>NRAS</i>-Mutant Melanoma: Results From the Expansion Arm of a Phase Ib, Open-Label StudyFilippo de Braud, Christophe Dooms, Rebecca S Heist, et al.
Pageof 4

Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
International Journal of Antimicrobial Agents|January 14, 2023
A single- and multiple-dose study to characterize the pharmacokinetics, safety, and tolerability of ceftolozane/tazobactam in healthy Chinese participantsNa Liu, Xiaohong Wang, Jixiang Zhu, et al.
Critical Care (London, England)|October 3, 2021
Ceftolozane/tazobactam probability of target attainment and outcomes in participants with augmented renal clearance from the randomized phase 3 ASPECT-NP trialAndrew F Shorr, Christopher J Bruno, Zufei Zhang, et al.
Drug Metabolism Reviews|March 8, 2017
Glucuronidation: driving factors and their impact on glucuronide dispositionGuangyi Yang, Shufan Ge, Rashim Singh, et al.
The AAPS Journal|June 15, 2023
Streamlining Food Effect Assessment - Are Repeated Food Effect Studies Needed? An IQ AnalysisFilippos Kesisoglou, Sumit Basu, Tejashree Belubbi, et al.
IEEE Journal of Biomedical and Health Informatics|February 24, 2022
A Comparison of Wearable Tonometry, Photoplethysmography, and Electrocardiography for Cuffless Measurement of Blood Pressure in an Ambulatory SettingRebecca Mieloszyk, Hope Twede, Jonathan Lester, et al.
The AAPS Journal|November 27, 2020
Correction to: Use of Physiologically Based Pharmacokinetic (PBPK) Modeling for Predicting Drug-Food Interactions: an Industry PerspectiveArian Emami Riedmaier, Kevin DeMent, James Huckle, et al.
The AAPS Journal|September 27, 2020
Use of Physiologically Based Pharmacokinetic (PBPK) Modeling for Predicting Drug-Food Interactions: an Industry PerspectiveArian Emami Riedmaier, Kevin DeMent, James Huckle, et al.
European Journal of Cancer (Oxford, England : 1990)|December 1, 2023
First-in-human study of naporafenib (LXH254) with or without spartalizumab in adult patients with advanced solid tumors harboring MAPK signaling pathway alterationsFilip Janku, Tae Min Kim, Gopakumar Iyer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 22, 2023
Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in <i>NRAS</i>-Mutant Melanoma: Results From the Expansion Arm of a Phase Ib, Open-Label StudyFilippo de Braud, Christophe Dooms, Rebecca S Heist, et al.
Pageof 4